iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
August 05 2024 - 7:00AM
iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a
clinical-stage biopharmaceutical company pioneering the discovery
and development of a new generation of immuno-oncology therapeutics
for patients, today announced the appointment of David Feltquate,
M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate
will be responsible for overseeing the Company’s clinical
development and regulatory strategies.
“As iTeos reaches a pivotal moment towards
recognizing our ambition to become a leading oncology company,
we’re excited to welcome Dr. Feltquate as Chief Medical Officer,”
said Michel Detheux, Ph.D., president and chief executive officer
of iTeos. “His leadership experience, track record in
immuno-oncology drug development, and insights into biomarker
development will prove invaluable as we continue to advance our
pipeline. We look forward to the integral role he will play in
shaping our clinical development strategy and in strengthening our
organization as we continue in a defining year for the
company.”
Dr. Feltquate brings to iTeos nearly 20 years of
immuno-oncology clinical development, translational medicine, and
diagnostic assay advancement experience. Prior to joining iTeos, he
was Chief Medical Officer at Palleon Pharmaceuticals where he
oversaw the clinical strategy and development of its
glyco-immunology therapeutics pipeline. Before that, Dr. Feltquate
was the Global Head of Hematology Development and Chair of the
Precision Medicine Leadership Team at Novartis. Previously, he held
numerous leadership positions at Bristol Myers Squibb including
Head of Oncology Early Clinical Development and Development Leader
for Ipilimumab / Nivolumab Life Cycle Management. As the Nivolumab
Clinical Head, Dr. Feltquate was responsible for the clinical
development of the first PD-1 inhibitor from proof of concept
through initial registrations in non-small cell lung cancer,
melanoma, and renal cell carcinoma. Dr. Feltquate earned a B.S. in
Biology from the Massachusetts Institute of Technology and an
M.D./Ph.D. in Immunology from the University of Massachusetts
Medical School. He completed internal medicine training at
Dartmouth Hitchcock Medical Center and medical oncology training at
Memorial Sloan Kettering Cancer Center.
“I am delighted to join iTeos at a time when the
company is accelerating its TIGIT franchise and strategically
focused on building a rich pipeline of new targets for patients in
need,” said Dr. Feltquate. “Being part of a company that is at the
forefront of developing an innovative oncology pipeline, ingrained
in a scientifically disciplined, data driven approach, represents
an incredible opportunity to bring novel and potentially
transformative therapies to patients.”
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of tumor
immunology and immunosuppressive pathways to design novel product
candidates with the potential to restore the immune response
against cancer. The Company’s innovative pipeline includes three
clinical-stage programs targeting novel, validated
immunosuppressive pathways designed with optimized pharmacologic
properties for improved clinical outcomes, including the
TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is
headquartered in Watertown, MA with a research center in Gosselies,
Belgium.
About Belrestotug (EOS-448/
GSK4428859A)Belrestotug is an Fc active human
immunoglobulin G1, or IgG1, monoclonal antibody (mAb) targeting T
cell immunoglobulin and immunoreceptor tyrosine-based inhibitory
motif domains (TIGIT), an important inhibitory receptor which
contributes to the suppression of innate and adaptive immune
responses against cancer. As an optimized high-affinity, potent
anti-TIGIT mAb, belrestotug is designed to enhance the antitumor
response through a multifaceted immune modulatory mechanism by
engaging with TIGIT and FcγR, a key regulator of immune responses
which induces cytokine release and antibody dependent cellular
cytotoxicity (ADCC). The therapeutic candidate is progressing in
multiple indications in collaboration with GSK.
Internet Posting of Information
iTeos routinely posts information that may be
important to investors in the 'Investors' section of its website
at www.iteostherapeutics.com. The Company encourages investors
and potential investors to consult our website regularly for
important information about iTeos.
Forward-Looking Statements
This press release contains forward-looking
statements. Any statements that are not solely statements of
historical fact are forward-looking statements. Words such as
“believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,”
“prepare,” “look,” “potential,” “possible” and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements include statements relating to the
potential benefits of David Feltquate’s appointment as the
Company’s Chief Medical Officer and the potential to bring novel
and transformative therapies to patients.
These forward-looking statements involve risks
and uncertainties, many of which are beyond iTeos’ control. Actual
results could materially differ from those stated or implied by
these forward-looking statements as a result of such risks and
uncertainties. Known risk factors include the following: the data
for our product candidates may not be sufficient for obtaining
regulatory approval to move into later stage trials or to
commercialize products; iTeos may not be able to execute on its
business plans, including meeting its expected or planned
regulatory milestones and timelines, research and clinical
development plans, and bringing its product candidates to market,
for various reasons, some of which may be outside of iTeos’
control, including possible limitations of company financial and
other resources, manufacturing limitations that may not be
anticipated or resolved for in a timely manner, negative
developments in the field of immuno-oncology, and regulatory, court
or agency decisions; and those risks identified under the heading
“Risk Factors” in iTeos’ Quarterly Report on Form 10-Q for the
period ended March 31, 2024 filed with the Securities and Exchange
Commission (SEC) as well as other SEC filings made by the Company
which you are encouraged to review.
Any of the foregoing risks could materially and
adversely affect iTeos’ business, results of operations and the
trading price of iTeos’ common stock. We caution investors not to
place undue reliance on the forward-looking statements contained in
this press release. iTeos does not undertake any obligation to
publicly update its forward-looking statements other than as
required by law.
For further information, please contact:
Investor Contact:Carl MauchiTeos Therapeutics,
Inc.carl.mauch@iteostherapeutics.com
Media Contact:media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Sep 2024 to Oct 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Oct 2023 to Oct 2024